Document is current
Any future updates will be listed below
-
Authors
Mogk, Jessica M. https://orcid.org/0000-0003-4102-7309
Matson, Theresa E.
Caldeiro, Ryan M.
Garza Mcwethy, Angela M.
Beatty, Tara
Sevey, Brandie C.
Hsu, Clarissa W.
Glass, Joseph E.
-
Funding
Funding for this research was provided by:
National Institute on Alcohol Abuse and Alcoholism (K01AA023859)
- License Information
-
More Information
Article History
Received: 20 December 2022
Accepted: 1 May 2023
First Online: 8 May 2023
Declarations
:
: The Kaiser Permanente Washington Human Subjects Review Office (FWA00002344) determined that this project is exempt from Institutional Review Board review according to federal regulations, per Category 2. This exempt research was conducted in accordance with the principles of the Belmont Report. Verbal informed consent was obtained from all the subjects enrolled in this study. All subjects participated voluntarily and received a small compensation.
: Not applicable.
: reSET<sup>®</sup> and reSET-O<sup>®</sup> are digital therapeutics for substance use disorder marketed by Pear Therapeutics (US), Inc. that are discussed in this manuscript. During a quality improvement project, Pear Therapeutics (US), Inc. provided digital therapeutic prescriptions at no cost to Kaiser Permanente Washington. Pear Therapeutics (US), Inc. was not involved in the current study and has not provided funding to the authors.
